Rhinosinusitis in hiv-infected children undergoing antiretroviral therapy

Summary

The association of protease inhibitors (PI) to antiretroviral therapy has generated sensible changes in morbidity and mortality of HIV-infected patients. **Aim:** Aims at evaluating the impact of this association on the prevalence of rhinosinusitis (RS) and CD4+ lymphocyte count in HIV-infected children. **Methods:** Retrospective cross-sectional study of the medical charts of 471 HIV-infected children. In 1996, protease inhibitors were approved for use as an association drug in antiretroviral therapy. Children were divided into two groups: one which did not receive PI and another which received PI after 1996. The prevalence of RS and CD4+ lymphocyte counts were compared between these groups. **Results:** 14.4% of HIV-infected children had RS. Chronic RS was more prevalent the its acute counterpart. Children under 6 years old who were taking protease inhibitors presented with a significant higher prevalence of acute RS. The association of PI with the antiretroviral regimen was associated to higher mean CD4+ lymphocyte count and lower prevalence of chronic RS. **Conclusions:** The use of protease inhibitors was associated to higher mean CD4+ lymphocyte count. Children under 6 years of age in antiretroviral therapy associated with PI presented a lower likelihood of developing chronic RS.

Keywords: children, haart, hiv infections, sinusitis.
INTRODUCTION

Worldwide dissemination of the Human Immunodeficiency Virus (HIV) has had a terrible impact on children. Based on 2004 data, the UNAIDS/WHO has estimated that 2.2 million children aged below 15 years are infected. The Brazilian Ministry of Health reported 13,786 cases in children aged below 15 years by December 2004. The advent of new antiretroviral drugs, especially protease inhibitors, has substantially reduced the mortality rate of HIV infection. A cross-sectional study from 2001 estimated that 13,286 children aged below 13 years by December 2004.2 The Brazilian Ministry of Health reported 13,286 cases in children aged below 13 years by December 2004.2

Children generally present six to eight upper respiratory virus infections a year.7 About 5% to 13% of these episodes progress to secondary bacterial rhinosinusitis.8 Most of these children that develop a bacterial infection respond well to medication. Some, however, progress to chronic rhinosinusitis, particularly those with a dysfunction of nasosinusal physiology or any type of immune deficiency. HIV-infected patients are at an increased risk of developing chronic rhinosinusitis.9

Zidovudine, a nucleoside reverse transcriptase inhibitor (NRTI), was developed in 1987, and became the first medication for the Acquired Immunodeficiency Syndrome (AIDS). Non-nucleoside reverse transcriptase inhibitors (NNRTI) were developed next. In 1996, new antiretroviral drugs - the protease inhibitors (PI) - were introduced.3 The association of these new drugs (usually 2 NRTI + 1 PI or 1 NRTI + 1 NNRTI + 1 PI) is known as the Highly Active Antiretroviral Therapy (HAART).

Although rhinosinusitis is more prevalent in HIV-infected children, data on changes in the prevalence of this disease in children after HAART was introduced remain sparse.

Thus, the purpose of this study was to assess changes in the prevalence and pattern of rhinosinusitis and CD4+ lymphocyte serum counts in a specific population of Brazilian HIV-infected children following the introduction of HAART.

MATERIAL AND METHOD

A cross-sectional study model was used to retrospectively review the files of 471 children aged from 0 to 12 years and 11 months with a prior diagnosis of HIV-infection seen at the HIV/AIDS Outpatient Unit from January 1990 to December 2004. Data analysis for this study was undertaken from January 1990 to December 2004; however, follow-up of these and new cases of HIV-infected children continues to be done in our outpatient unit. The Research Ethics Committee of our institution approved the study (protocol number 153/03).

All children aged from 0 to 12 years and 11 months bearing a serological diagnosis of HIV infection (positive Elisa and/or Western Blot tests) that were seen at the outpatient unit from January 1990 to December 2004 were included in this study. Exclusion criteria were absence or irregular use of antiretroviral therapy or use of one or more antiretroviral drugs during 4 months or less. Twelve children were excluded from the sample. The 459 children included in the study were divided into two groups, as follows: those using regimens without protease inhibitors (Anti-Retroviral Therapy - ART) totaling 236 children, and those using HAART totaling 223 children. The mean duration of therapy among patients given ART was 14 ±4 months; among patients given HAART it was 9 ±2 months.

The same specialist (IDM) undertook a complete otorhinolaryngological physical examination in the first ambulatory visit. Rhinosinusitis was diagnosed and classified into acute and chronic forms according to the 1998 Brazilian Consensus on Rhinosinusitis of the ABORL-CCF (1 Consenso Brasileiro sobre Rhinosinusitis da ABORL-CCF). Thus, acute rhinosinusitis was diagnosed when children presented:10

a) A compatible medical history, duration up to 4 weeks (nose block, yellowish rhinorrhea, fever, headache, coughing and/or oropharyngeal irritation).

b) A suggestive physical examination (mucosal edema and hyperemia, purulent discharge in the nose, oropharyngeal secretion originating in the rhinopharynx and/or pain on palpating the area of the sinuses).

c) A plain radiograph of the paranasal sinuses in orthostatism (showing mucosal edema and/or sinus opacification).

Children were diagnosed as having chronic rhinosinusitis when presenting:10

a) A compatible medical history, duration over 4 weeks (yellowish rhinorrhea, coughing, cacosmia and/or feeling of heaviness in the head).

b) A suggestive physical examination (nasal and/or retronasal purulent discharge).

c) Computed tomography of the paranasal sinuses (mucosal edema, opacification of sinuses and/or nasal cavity).

Some children underwent nasofibrolaryngoscopy, although this exam was not done routinely. A blood sample was taken to measure the serum CD4+ lymphocyte count on the same day of consultation.

Statistical analysis: Analysis of the 459 children was stratified by age, subdivided into two groups: 0 to 5 years and 11 months, and 6 to 12 years and 11 months. We calculated and compared the prevalence of rhinosinusitis in each age group, and the CD4+ T lymphocyte counts among ART and HAART patients. We applied the Pearson chi-square test and the Fisher exact test for cate-
gorical variables. For continuous variables we applied the Student t test for independent samples when there was homocedasticity and equality of variances; otherwise we used the non-parametric Mann-Whitney U test. P values below 0.05 were considered statistically significant. The software Statistical Package for Social Sciences (SPSS® for Windows 10.0, SPSS Inc., Chicago, IL) was used for data analysis.

RESULTS

Table 1 shows demographic data (age, sex, origin and HIV infection route) and the antiretroviral regimens given to the 459 children. Immunological classification data about the children were taken from their medical files, and were based on the 1994 Center for Disease Control Revised Classification System for Human Immunodeficiency Infection in Children Less than 13 Years of Age,11 these are summarized in Table 2. Among the 459 children, 66 (14.4%) presented rhinosinusitis, of which 24 (13.6%) were aged below 5 years and 11 months, and 42 (14.8%) were aged from 6 to 12 years and 11 months (p = 0.8). Thirty-six children (7.8%) presented chronic rhinosinusitis, and 30 children (6.5%) presented acute rhinosinusitis. Chronic rhinosinusitis was more prevalent in both age groups.

Table 3 shows the prevalences of rhinosinusitis and the distribution according to age and use of HAART. Among children aged from 0 to 5 years and 11 months, those that were given HAART had a higher prevalence of acute rhinosinusitis (12.9% vs. 1.9%, p=0.007). The relative risk of HAART-treated children aged below 5 years and 11 months of presenting acute rhinosinusitis was 2.2 times (95% CI: 1.6 - 3.1) the risk of ART-treated children presenting the same condition. The observed differences in the prevalence of chronic rhinosinusitis were not statistically significant.

There were no statistically significant differences on the prevalences of acute and chronic rhinosinusitis among children given HAART and children given ART in the 6 to 12 years and 11 months age group.

Table 1. Data on demography and antiretroviral regimens in 459 HIV-infected children.

| Sex          | Male       | 258 (56.2%) | Female     | 201 (43.8%) |
|--------------|------------|-------------|------------|-------------|
| Age          |            |             |            |             |
| Mean ± Standard deviation (years) | 6.6 ± 2.5 |
| 0 to 5 years and 11 months | 176 (38.3%) |
| 6 to 12 years and 11 months | 283 (61.7%) |
| HIV - transmission |            |             |            |             |
| Vertical     | 387 (84.3%) |
| Blood transfusion | 18 (3.9%) |
| Indeterminate | 54 (11.7%) |
| Origin       |            |             |            |             |
| Referred from Hospitals | 362 (79.0%) |
| Household    | 97 (21.0%) |
| Antiretroviral therapy |            |             |            |             |
| 2 NRTI PI    | 133 (29.0%) |
| NRTI NNRTI PI | 90 (19.6%) |
| AZT DDI      | 45 (9.8%) |
| AZT 3TC      | 82 (17.9%) |
| AZT only     | 90 (19.6%) |
| DDI only     | 19 (4.2%) |

Table 2. Distribution of the 459-children sample into immune classes according to the age group and use or not of HAART.

| Immune class | 0 to 5 years and 11 months (n = 176) | 6 to 12 years and 11 months (n = 283) |
|--------------|--------------------------------------|--------------------------------------|
|              | HAART (n = 70)                      | ART (n = 106)                       | HAART (n = 153)                        | ART (n = 130)                        |
| A1           | 12 (17.1%)                          | 5 (4.7%)                           | 54 (35.3%)                            | 22 (16.9%)                           |
| A2           | 32 (45.7%)                          | 21 (19.8%)                         | 28 (18.3%)                            | 13 (10.0%)                           |
| A3           | 1 (1.4%)                            | -                                  | -                                    | -                                    |
| B1           | 1 (1.4%)                            | -                                  | 36 (23.5%)                            | 24 (18.5%)                           |
| B2           | 19 (27.1%)                          | 42 (39.6%)                         | 24 (15.7%)                            | 37 (28.5%)                           |
| B3           | 1 (1.4%)                            | 3 (2.8%)                           | -                                    | 1 (0.8%)                             |
| C1           | -                                   | -                                  | 1 (0.7%)                             | -                                    |
| C2           | 3 (4.3%)                            | 26 (24.5%)                         | 7 (4.5%)                             | 26 (20.0%)                           |
| C3           | 1 (1.4%)                            | 9 (8.5%)                           | 3 (2.0%)                             | 7 (5.4%)                             |

NRTI = Nucleoside Reverse Transcriptase Inhibitor: Zidovudine (AZT), Didanosine (DDI), Lamivudine (3TC); PI = Protease Inhibitor: Indinavir, Ritonavir, Saquinavir, Nelfinavir; NNRTI = Non-Nucleoside Reverse Transcriptase Inhibitor: Nevirapine, Efavirenz.
Tables 4 and 5 present the mean serum CD4+ T lymphocyte counts in each age group. In the 0 to 5 years and 11 months age group children with chronic rhinosinusitis had serum CD4+ T lymphocyte counts on average 65.4 ±58 x 10^-9 cell/L below the count of children without rhinosinusitis (p = 0.002). There were no statistically significant differences among the mean serum CD4+ T lymphocyte counts among patients with or without acute rhinosinusitis in this age group.

In children aged from 6 to 12 years and 11 months, those with acute rhinosinusitis had serum CD4+ T lymphocyte counts on average 173.3 ±42 x 10^-9 cell/L above the count of similarly aged children without acute rhinosinusitis (p < 0.001); children with chronic rhinosinusitis had CD4+ T lymphocyte counts on average 154.2 ±39 x 10^-9 cell/L below the count of similarly aged children without chronic rhinosinusitis.

Children given HAART had mean counts above the counts of children given ART, regardless of the age group; these differences were statistically significant (p < 0.001) and are shown on Table 6.

### DISCUSSION

Chronic rhinosinusitis has been reported as a frequent disease in HIV-infected adult patients. Its pre-

---

**Table 3.** Prevalences of rhinosinusitis in the sample children according to age and use or not of HAART.

| Age group                  | 0 to 5 years and 11 months | 6 to 12 years and 11 months |
|----------------------------|----------------------------|-----------------------------|
|                            | HAART (n=70)  | ART (n=106)  | p             | HAART (n=153) | ART (n=130)  | p             |
| Acute rhinosinusitis       | 9 (12.9%)     | 2 (1.9%)     | 0.007         | 11 (7.2%)     | 8 (6.2%)     | 0.9           |
| Chronic rhinosinusitis     | 3 (4.3%)      | 10 (9.4%)    | 0.3           | 13 (8.5%)     | 10 (7.7%)    | 1.0           |
| Total                      | 12 (17.1%)    | 12 (11.3%)   | 0.4           | 24 (15.7%)    | 18 (13.8%)   | 0.8           |

HAART = Highly Active Anti-Retroviral Therapy

**Table 4.** Serum CD4+ T lymphocyte counts according to the presence of rhinosinusitis in children aged from 0 to 5 years and 11 months.

| Rhinosinusitis | CD4 (x10^-9 cell/L) | p  |
|----------------|---------------------|----|
| Acute          |                     |    |
| Yes (n = 11)   | 846.9 ± 174.6       | 0.3|
| No (n = 165)   | 781.5 ± 189.5       |    |
| Chronic        |                     |    |
| Yes (n = 13)   | 633.8 ± 187.7       | 0.002|
| No (n = 163)   | 797.7 ± 184.1       |    |

**Table 5.** Serum CD4+ T lymphocyte counts according to the presence of rhinosinusitis in children aged from 6 to 12 years and 11 months.

| Rhinosinusitis | CD4 (x10^-9 cell/L) | p  |
|----------------|---------------------|----|
| Acute          |                     |    |
| Yes (n = 19)   | 665.3 ± 131.1       | <0.001|
| No (n = 264)   | 492.0 ± 183.1       |    |
| Chronic        |                     |    |
| Yes (n = 23)   | 362.0 ± 136.4       | <0.001|
| No (n = 260)   | 516.2 ± 183.8       |    |

**Table 6.** Serum CD4+ T lymphocyte counts according to the age group and use of HAART.

| Age group                  | 0 to 5 years and 11 months | 6 a 12 anos e 11 meses |
|----------------------------|----------------------------|------------------------|
|                            | (n = 176)                  | (n = 283)              |
| CD4 (x 10^-9 cell/L)       | p                          | CD4 (x 10^-9 cell/L)   | p             |
| HAART (n = 223)            | 872.7 ± 158.1              | <0.001                 | 539.1 ± 166.8 | <0.001        |
| ART (n = 236)              | 728.1 ± 186.0              |                         | 461.9 ± 197.1 |               |

HAART = Highly Active A
valence, however, varies according to the study, probably due to different diagnostic methods for rhinosinusitis and different methods. There are few published papers on the prevalence of rhinosinusitis in HIV-infected children; in these, results vary widely. Mofenson et al. found a 10.6% prevalence in 376 HIV-positive children. Chen et al. found a 20% prevalence in his series. Chaloryoo et al. studied 250 Thai children with AIDS and found a 0.8% prevalence. The prevalence of chronic rhinosinusitis among the 459 HIV-infected children referred to otorhinolaryngological evaluation in our study was 7.8%. Chaloryoo’s low prevalence stands out among these numbers. This may be explained by the fact that his series consisted of children with full-blown AIDS, therefore with more significant medical intercurrences such as hepatosplenomegaly (82.85%) and persistent pneumonia (64.4%). In this situation chronic rhinosinusitis may have been underdiagnosed.

It should be said that all patients in our study were being given antiretroviral therapy, albeit in heterogeneous regimens. In 1991, the Brazilian government started distributing Zidovudine free of charge to HIV-infected patients; the Law 9313/96 establishes that 100% of HIV-infected patients are assured free antiretroviral therapy, including protease inhibitors.

The prevalence in our series was higher in older children, which would be expected since the paranasal sinuses in younger children are not always fully developed.

There are no published studies comparing the prevalence of rhinosinusitis according to the type of antiretroviral therapy (HAART or ART). In our sample, children aged below 5 years and 11 months and given HAART had a higher prevalence of acute rhinosinusitis, thus a comparatively lower tendency to chronify. This may be due to the restoration of immune function in these children, who therefore respond more rapidly to germs in the paranasal cavities. Mizzia et al. studied the prevalence of oitis and found similar results: the prevalence of acute oitis media in the same age group was higher in children given HAART.

The lack of any statistically significant difference in the prevalence of acute and chronic rhinosinusitis among children aged over 6 years, given HAART or ART, does not in itself suggest failure of highly active therapy (or even non-compliance to therapy); children who tended to chronify had lower mean serum CD4+ T lymphocyte counts.

Children with chronic rhinosinusitis in both age groups had lower serum CD4+ T lymphocyte counts compared to those without chronic rhinosinusitis. Castillo et al. studied adult patients with chronic rhinosinusitis and concluded that relapses were more frequent in patients with serum CD4+ T lymphocyte counts below 200/mL. In Barcelona, García-Rodríguez et al. studied 74 adult HIV-positive patients and found that low serum CD4+ T lymphocyte counts were associated with rhinosinusitis.

Mofenson et al. studied 376 HIV-infected children and found that serum CD4+ T lymphocyte counts were not different in children with and without rhinosinusitis. In this study, the authors did not separate children with acute or chronic rhinosinusitis. The sample consisted mainly of younger children with acute rhinosinusitis. Mofenson et al.‘s results are thus similar to ours in the group aged below 5 years and 11 months with acute rhinosinusitis; in this subgroup, serum CD4+ T lymphocyte counts were not different among children with and without rhinosinusitis (Table 4).

In our series the use of HAART improved the immune system of these children; their mean serum CD4+ T lymphocyte counts were higher compared to children given ART (Table 6).

Many factors may be involved for a nasosinusal condition to become chronic, such as the presence or absence of allergies or anatomical features that hinder the success of standard medical therapy.

**FINAL COMMENTS**

Our results show that rhinosinusitis in children aged below 5 years tended to chronify less often, probably due to an improved immune system. It should be noted, however, that given the cross-sectional nature of our study, these results do not imply causality. The number of children with rhinosinusitis was not that high, which may explain the lack of statistical significance in older children. Additional prospective studies are needed to assess more effectively the effect of HAART on the onset of rhinosinusitis in children.

In general these objections do not invalidate our study; it is, undoubtedly, one of the largest series of rhinosinusitis in HIV-infected Brazilian children.

**REFERENCES**

1. Granados JMS, Amador JTR, Miguel SF, Tomé MIG, Conejo PR, Vivas PF et al. Impact of highly active Anti-retroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22:863-7.
2. Ministério da Saúde. Secretaria de Vigilância em saúde. Programa nacional de DST e AIDS. Casos de AIDS (números e percentual) em indivíduos com 13 anos de idade ou mais, segundo categoria de exposição hierarquizada por sexo e ano de diagnóstico. Brasil, 1980-2004. Boletim Epidemiológico AIDS e DST. 1(1):32, 2004.
3. Disponível em: http://www.aids.gov.br/final/dados/BOLETIM2.pdf. Acessado em 2 de novembro de 2007.
4. Hoare S. HIV infection in children – impact upon ENT doctors. Int J Pediatr Otorhinolaryngol. 2003;67 Suppl 1:85-90.
5. Bosco VL, Birman EG. Oral manifestations in children with AIDS and controls. Pesqui Odontol Bras. 2002;16(1):7-11.
6. Gottmacher SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GRIII et al. Effects of Combination Therapy Including Protease Inhibitors on Mortality Among Children and Adolescents Infected with HIV-1. N Engl J Med. 2001;345(21):1522-8.
7. Miziara ID, Valentini M, Romano FR, Miniti A. Changing patterns of buccal manifestations in AIDS. Rev Laryngol Otol Rhinol. 2002;123(4):231-4.
8. Ramadan HH. Pediatric sinusitis: update. J Otolaryngol. 2005;34 Suppl 1:14-7.
9. Sande MA, Gwaltney JM Jr. Acute community-acquired bacterial sinusitis: continuing challenges and current management. Clin Infect Dis. 2004;39:151-8.
10. Shah AR, Hairston JA, Tami TA. Sinusitis in HIV: microbiology and therapy. Curr Allergy Asthma Rep. 2005;5(6):495-9.
11. I Consenso Brasileiro sobre Rinossinusite 65 / 3 - ABORL-CCF - Recife - 1998.
12. Disponível em: http://www.rborl.org.br/portugues/consensos.asp. Acessado em 2 de novembro de 2007.
13. Caldwell MB, Oxtoby MJ, Simonds RJ, Lindegren ML, Rogers MF. 1994 Revised Classification System for Human Immunodeficiency Virus Infection in Children Less Than 13 Years of Age. Morbidity and Mortality Weekly Report. September 30 1994;43(RR-12):1-10.
14. Chen AY, Ohlms LA, Stewart MG, Kline MW. Otolaryngologic disease progression in children with human immunodeficiency virus infection. Arch Otolaryngol Head Neck Surg. 1996;122(12):1360-3.
15. Chaloryoo S, Chotpitayasunondh T, Chiengmai PN. AIDS in ENT in children. Int J Pediatr Otorhinolaryngol. 1998;44:103-7.
16. Weber R, Pinheiro-Neto CD, Miziara ID, Araújo-Filho BC. Impacto da HAART na prevalência de oíttes médias crônicasem crianças brasileiras infectadas pelo HIV. Rev Bras Otorrinolaringol. 2006;72(4):509-14.
17. Castillo L, Roger PM, Haddad A, Meyer JM, Santini J, Demard F. Chronic sinusitis in patients infected by HIV: therapeutic strategies. Ann Otolaryngol Chir Cervicofac. 1999;116(3):162-6.
18. García-Rodríguez JF, Corominas M, Fernandez-Viladrich P, Monfort JL, Dicenta M. Rhinosinusitis and atopy in patients infected with HIV. Laryngoscope. 1999;109(6):939-44.
19. Mofenson LM, Korelitz J, Pelton S, Moye J Jr, Nugent R, Bethel J. Sinusitis in children infected with human immunodeficiency virus: clinical characteristics, risk factors, and prophylaxis. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Clin Infect Dis. 1995;21(5):1175-81.
20. De Benedetto M, Salerni L, De Benedetto L, Passali GC, Passali D. Rhinosinusitis: etiopathogenesis and antimicrobial therapy, an update. Acta Otorhinolaryngol Ital. 2006;26(1 Suppl 82):5-22